Novo Nordisk's ziltivekimab fails phase 3 ZEUS trial; shares fall about 9%
The setback involves an experimental drug, not Novo's approved semaglutide medicines such as Ozempic and Wegovy, whose approval status is unchanged.
Novo Nordisk said its phase 3 ZEUS trial of ziltivekimab did not meet its primary endpoint in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation, according to a company announcement dated July 31, 2026 [1]. Shares in the Danish drugmaker fell about 9% that day, extending a run of pipeline disappointments for the maker of Ozempic and Wegovy [2].
Ziltivekimab was being tested in people with heart and kidney disease and inflammation, not as a weight-loss drug [1]. Novo filed the ZEUS update as a company announcement rather than a press release; the company says company announcements are intended for investors while press releases are for the media [1]. The sector research service ObesityIntel describes the failure as a setback to Novo's attempt to build a cardiometabolic business outside GLP-1 drugs [2].
Several basic facts about the trial have not been reported. These include how many people were enrolled in ZEUS, what the primary endpoint measured, how far the result fell short, and whether any secondary endpoints were met [1][2]. Novo has not said whether it will keep developing ziltivekimab or what the result means for people who took part in the trial [1][2]. The size of the impairment has not been disclosed [2].
The roughly 9% share decline on July 31 followed other setbacks for Novo's pipeline. ObesityIntel notes that the company's CagriSema weight-loss candidate produced about 22.7% weight loss in trials, below the roughly 25% the company had hoped for, that Novo changed chief executives in August 2025 with the appointment of Mike Doustdar, and that it cut about 9,000 jobs [2]. Novo has also slipped behind Eli Lilly in the obesity market [2].
The failure is a pipeline event rather than a collapse in the current business. In a report dated Aug 4, 2026, Novo reported adjusted operating profit of DKK 33,389 million for the second quarter of 2026 and raised its full-year outlook [1]. ObesityIntel's event calendar lists the same quarterly results for Aug 5, 2026 [2].
Why it matters for patients
Ziltivekimab is not an approved treatment; it was still in phase 3 testing [1]. Novo's announcement covers only this drug, and it does not change the status of the company's approved medicines, including semaglutide, sold as Ozempic and Wegovy [1][2].
For people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation, the result means one possible future option is not moving forward now. Whether Novo continues testing ziltivekimab in any other group of patients has not been reported [1][2].
For people taking Novo's approved semaglutide products, the immediate practical questions are about supply, price and coverage rather than this trial. Novo has not reported any effect of the ZEUS failure on GLP-1 supply, pricing, insurance coverage or research spending on its marketed medicines [1][2]. Whether the share decline leads to any change in the company's spending priorities has also not been reported [2].
What happens next
Novo will record a non-cash impairment in the third quarter of 2026 tied to the ZEUS failure; the amount has not been disclosed [2].
The company faces a US regulatory decision on CagriSema, its once-weekly GLP-1 and amylin combination for weight management, in the second half of 2026, according to ObesityIntel [2].
No date has been reported for any further ZEUS data or for a new trial of ziltivekimab [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.